Pancreatic ductal adenocarcinoma (PDAC) · line 2 · Nal-IRI + 5-FU/LV (PDAC, 2L nanoliposomal irinotecan)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-NAL-IRI-5FU-LV-PDAC |
| ID | IND-PDAC-METASTATIC-2L-NAL-IRI |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-PDAC |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NAPOLI1-WANG-GILLAM-2016 SRC-NCCN-PANCREATIC-2025 |
Notes
NAPOLI-1 (PMID 26524560) is the landmark RCT establishing nal-IRI+5-FU/LV as Category 1 2L post-gemcitabine mPDAC. FDA approved October 2015 (ONIVYDE). ONIVYDE not registered in Ukraine — significant access barrier. FOLFOX or modified FOLFOX (NCCN-listed 2L option) is the accessible fallback. Algorithm partner: ALGO-PDAC-METASTATIC-2L routes by prior 1L backbone.
Used By
Algorithms
ALGO-PDAC-METASTATIC-2L- ALGO-PDAC-METASTATIC-2L